PepGen
PepGen is a clinical stage biotech developing next-generation oligonucleotide therapies for patients with Duchenne's Muscular Dystrophy and other rare diseases. The company went public in May 2022.
- What
- Life Sciences
- When
- Mar 2018
- CEO
- James McArthur
- Status
- Public
- Investment
- Active
- OSE Board Director
- Chris Ashton